Detalhe da pesquisa
1.
The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
Mol Pharmacol
; 99(4): 256-265, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547249
2.
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Neurobiol Dis
; 159: 105507, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34509608
3.
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose Projections.
ACS Med Chem Lett
; 15(1): 123-131, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38229758
4.
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease.
ACS Med Chem Lett
; 14(2): 146-155, 2023 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36793422
5.
Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
J Pharmacol Exp Ther
; 338(2): 622-32, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21558436
6.
Characterization of PCS1055, a novel muscarinic M4 receptor antagonist.
Eur J Pharmacol
; 782: 70-6, 2016 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27085897
7.
The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.
Neuropsychopharmacology
; 38(13): 2717-26, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23907402
8.
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.
Sci Transl Med
; 2(52): 52ra73, 2010 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-20926834